Autopsy report · NCT05162365
A Safety, Tolerability, and Efficacy Study of IBI314 in Ambulatory Patients With COVID-19
Cause of deathFunding or business, also regulatory or ethics
“The company decision that terminated the further develop of the molecule and had notified FDA about the termination as well.”
Life of this trial
- Ran for about 10 months before it stopped.
- 248 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Sponsor type
- Industry
- Conditions
- COVID-19
- Interventions
- IBI314; Placebo
- Participants
- 248
- Sites
- 19
- Countries
- United States
Trials that died the same way
- Study to Evaluate Safety of Vitamin D Receptor Activators in Patients Ages 0 to 16 With Chronic Kidney Disease Stage 5 Receiving Peritoneal Dialysis Within Current Clinical Practice
“Terminated after FDA agreement.” - A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Single and Multiple Ascending Doses of GDC-0334 and the Effect of Food on the Pharmacokinetics of GDC-0334 in Healthy Adult Participants
“Molecule development was terminated” - Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer
“US FDA is streamlining the Biosimilar development. Thus, Biocon decided to terminate the study.” - A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes
“The entire drug development program for this molecule was sold to another company.” - A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
“The study was terminated due to regulatory approval of newer therapeutic options and slower than anticipated accrual.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.